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Supplementary Table 1. Primer details for qRT-PCR 
Rat 






























Forward Primer Reverse Primer Amplicon 
Size 
Acta2 GCT ATT CAG GCT GTG CTG TC GGT AGT CGG TGA GAT CTC GG 163bp 
Arhgap1 TTG TGG AAG TAG CCG GTG AT CTT GTT GTC ACT GGT CAG GC 188bp 
Aspn ACA ACG GGA TAG AAC CAG GG GTT GTT TCC AAG ACC CAG CC 200bp 
Bdnf TGG CTG ACA CTT TTG AGC AC GTT TGC GGC ATC CAG GTA AT 188bp 
Cntf CCA CAG GCA CAA AAT CCA CA TCC CAG GAA ACA AGT GAG CT 176bp 
Ctgf TGC CAG TGG AGT TCA AAT GC GTG TCC CTT ACT TCC TGG CT 169bp 
Cyp1a1 CCA TGA TGA CCA AGA GCT GC TGG CCC TTC TCA AAT GTC CT 207bp 
Cyp1b1 GAC GAT GCG GAG TTC CTA GA AAG TTG CTG AAG TTG CGG TT 164bp 
Fgf9 GAC AGT GGA CTC TAC CTC GG CCG TTT AGT CCT GGT CCC TT 210bp 
Grem1 TAG AGG CCA GAA GAA CCA GC CAA AGC CAA CTA CAG CCC TG 216bp 
Igf2 GGG ACG TGT CTA CCT CTC AG ATG ACG TTT GGC CTC TCT GA 191bp 
Igfbp3 CGT CCA CAT CCC AAA CTG TG TGA GGC AAT GTA CGT CGT CT 158bp 
Ihh AGG ACC GTC TGA ACT CAC TG CAC GGT CTG AGG TGG TGA TA 153bp 
Itga8 AGA AAT GAG GGA GAA GGG GC CGA GGA ACA GCA AAT CGG AG 215bp 
Lyve1 ACT TGC AGC TAT GGA TGG GT GAA AAC TCT GTT GCG GGT GT 233bp 
Mcpt1 TAA TTC CCT TGC CTG GTC CC GGA ACT TCC CAC ACA GAC CT 194bp 
Mmp14 GTG ACG GGA ACT TTG ACA CC TTT GCC ATC CTT CCT CTC GT 179bp 
Mmp17 AAG GCA CCT ACC CAG AAG TC GAG ACC CAC AAT GCT CTC CT 233bp 
Mrc1 TGG ATG GAT GGG AGC AAA GT GCT GCT GTT ATG TCT CTG GC 165bp 
Nefm CTA TGC CCA AAT CAC CCG TG CTT CTC TTT CAC CGG GGA CT 206bp 
Ngb CGC CCG GAG TCA GAG CTG AT GTT GGT CAC TGC AGC ATC AA 228bp 
Ptn GTC CCA GCA ATA TCA GCA GC CAC ACA CTC CAC TGC CAT TC 159bp 
Sfrp5 CAC TCA GAC ACC CAG GTC TT AGA TCT TGG TCA CTG GAG GC 241bp 
Tgfb2 AAG CAA GCC GGT GAA ATG TT TCA TGC TGG CTT CTA GAC CC 155bp 
Vcan CCG AAG CAG AGT GTA CAA GC ATC AGG GAG AGG GAA GCA TG 218bp 
 
Supplementary Table 2: The ten most altered transcripts (by fold change) in the urinary bladder of diabetic rats compared to control rats.  Transcripts 
(with known gene symbols) were sorted according to fold-change (p<0.0) 
 












fdr p value 
1369113_at Grem1 gremlin 1 27.9 
0.00052
4 
1.69E-07 1370269_at Cyp1a1 
cytochrome P450, family 
1, subfamily a, 
polypeptide 1 





10.9 1.35E-05 8.70E-10 1370059_at Nefl 
neurofilament, light 
polypeptide 
-8.1 0.000218 2.81E-08 
1384035_at Ildr2 
immunoglobulin-like domain 
containing receptor 2 
7.7 0.00048 1.39E-07 1387319_at Ccl11 
chemokine (C-C motif) 
ligand 11 







3.92E-05 1370355_at Scd1 
stearoyl-Coenzyme A 
desaturase 1 
-4.4 0.002957 7.23E-06 
1374166_at Adprhl1 ADP-ribosylhydrolase like 1 4.9 
0.00392
9 
1.06E-05 1371260_at Mcpt2 mast cell protease 2 -3.7 0.213053 0.019379 
1381504_at Aspn asporin 4.8 
0.00147
5 
1.08E-06 1369572_at Mcpt1 mast cell protease 1 -3.1 0.260783 0.029299 
1384564_at Fam159b 
family with sequence similarity 




1.70E-06 1387208_at Ngb neuroglobin -3.1 0.000392 7.57E-08 
1379022_at Adamts8 
ADAM metallopeptidase with 




0.000222 1370363_at Ces1d carboxylesterase 1D -3.0 0.027377 0.000411 
1390051_at Mtus2 
microtubule associated tumor 




3.70E-06 1368990_at Cyp1b1 
cytochrome P450, family 
1, subfamily b, 
polypeptide 1 
-3.0 0.060406 0.001777 







spindlin-2-like /// spindlin 
family, member 2A 
-2.9 0.004483 1.66E-05 
Supplementary Table 3: The ten most altered transcripts (by fold change) in the urinary bladder of sucrose-treated rats compared to control rats 
Transcripts (with known genes) were sorted according to fold-change (p<0.05) 
 

















fdr p value 










3.2 0.742008 0.001312 1383117_at Pxmp4 
peroxisomal 
membrane protein 4 







0.93595 0.044878 1387319_at Ccl11 
chemokine (C-C 
motif) ligand 11 








actin, alpha 2, 
smooth muscle, 





0.500296 0.000197 1368990_at Cyp1b1 
cytochrome P450, 
family 1, subfamily 
b, polypeptide 1 
-3.0 0.93595 0.00797 
1380866_at LOC365985 
similar to adenylate 
kinase 5 isoform 1 




-2.7 0.93595 0.011909 
1387410_at Nr4a2 
nuclear receptor 
subfamily 4, group 
A, member 2 
2.0 
 







2.0 0.93595 0.027788 1393421_at Pxmp4 
peroxisomal 
membrane protein 4 
-2.6 0.93595 0.037052 
1370405_at Mcpt1l1 
mast cell protease 
1-like 1 
2.0 0.93595 0.026427 1393645_at Mageb16 
melanoma antigen 











C1q and tumor 
necrosis factor 





Supplementary Table 4: The ten most altered transcripts (by fold change) in the urinary bladder of sucrose-treated rats compared to diabetic rats 
Transcripts (with known genes) were sorted according to fold-change (p<0.05) 
 
















fdr p value 
1388202_at RT1-EC2 
RT1 class Ib, locus 
EC2 6.4 0.418079 0.020582 1392074_at Cped1 
cadherin-like and PC-
esterase domain 
containing 1 -7.1 0.227515 0.003579 
1370059_at Nefl 
neurofilament, light 
polypeptide 4.6 0.024615 1.35E-05 1369113_at Grem1 gremlin 1 -6.7 0.136106 0.000727 
1370269_at Cyp1a1 
cytochrome P450, 
family 1, subfamily a, 
polypeptide 1 4.2 0.470809 0.029116 1374683_at Sgcg 
sarcoglycan, gamma 
(dystrophin-associated 




61 4.1 0.298173 0.007669 1371065_at 
LOC688090 /// 
RT1-Bb 
similar to RT1 class II 
histocompatibility 
antigen, B-1 beta chain 
precursor (RT1.B-bet -5.8 0.585529 0.064054 
1369217_at Nr4a3 
nuclear receptor 
subfamily 4, group A, 







reductase M2 -5.3 0.026228 2.19E-05 
1370355_at Scd1 
stearoyl-Coenzyme A 
desaturase 1 3.7 0.055419 0.000122 1372685_at Cdkn3 
cyclin-dependent kinase 




RT1 class I, locus 
CE10 /// RT1 class 
Ib, locus EC2 3.7 0.453545 0.026499 1392053_at Mmrn1 multimerin 1 -3.9 0.024615 1.13E-05 
1370150_a_at Thrsp 
thyroid hormone 
responsive 3.1 0.207612 0.002737 1381504_at Aspn asporin -3.8 0.04268 4.80E-05 
1369268_at Atf3 
activating 
transcription factor 3 3.1 0.491024 0.03272 1368224_at Serpina3n 
serine (or cysteine) 
peptidase inhibitor, 
clade A, member 3N -3.6 0.229877 0.00374 
1373759_at Fosb 
FBJ osteosarcoma 
oncogene B 2.9 0.431716 0.022697 1376799_a_at Crlf1 
cytokine receptor-like 
factor 1 -3.4 0.003826 1.23E-07 
Supplementary Table 5.  Indices of Diabetes.   At 16 weeks, db/db mice were significantly heavier 
than their lean controls, hyperglycaemic and polyuric. Statistical analysis was conducted using an 












Blood glucose (mg/dl) 
db/lean mice 
(16) 
30.3 ± 2.0 22.9 ± 10.0 145.8 ± 21.1 
db/db mice  
(16) 
50.4 ± 4.5**** 86.4 ± 58.0**** 605.2 ± 93.6**** 
 




Supplementary Figure 1.  Gene normalisation and Principal Component analysis plots 
for Affymetrix arrays.  Gene expression analysis quantile normalisation, and background correction 
were conducted using RMA in Bioconductor and differential expression was done with limma in 
Bioconductor (PMID: 15461798). Boxplots show gene expression before (A), and after 
normalisation (B).  Gene lists of differentially expressed genes were controlled for false discovery 
rate (fdr) errors using the method of QVALUE [24]. (C) Principal component analysis (PCA) was 
performed with Partek Genomics Suite (Partek Inc., USA.), Study 1: control n=3; diabetic n=4; Study 
2: control n=3, diabetic n=5 and sucrose-treated n=4.  
1298 197     169
D vs C
S vs C
Supplementary Figure  2.
Supplementary Figure 2 GeneVenn analysis of significant transcriptomic changes in 
diabetic and sucrose-treated rats compared with controls. Differential gene expression was 
filtered by P value<0.05, a fold change > ± 1.3, transcripts with low threshold expression (<50) in all 
groups were excluded from analysis. Dysregulation of only 169 transcripts were common to both 
diabetic and sucrose-treated rats compared with control, highlighting the greater impact of DM, 






























































































Supplementary Figure 3. Validation of array. Relative expression of selected transcripts (A) 
upregulated in array (diabetic versus control comparison: p and fdr<0.05) (B) downregulated 
in array (diabetic versus control comparison: p and fdr<0.05) and (C) not significantly altered 
in array (p and fdr>0.05) compared to control levels shows good reproducibility (control n=5, 
diabetic n=6; sucrose-treated n=4; p<0.05, one way ANOVA followed by Tukey’s posthoc 
test, or Kruskal-Wallis and Dunns multiple comparison test, as appropriate for data). (D-I) 
Brain-derived neurotrophic factor (BDNF)-immunoreactivity (-ir: Abcam AB108319; 1:200) 
and (J-O) Neurotrimin-ir (EMD Millipore, AB2280; 1;250) were both detected in the 
urothelium (U) of control, DM and sucrose-treated rats. Signals for the two proteins were 
prominent in the detrusor smooth muscle (SM) layer of diabetic rats but appeared minimal in 
bladder SM of control rats. Sucrose-treated rats also showed –ir for both BDNF and 
neurotrimin in the bladder SM but these signals appeared less prominent than those in the 
diabetic rats. (P) negative control (minus primary antibody, diabetic rat tissue section). Scale 
bar = 50µm; * = bladder lumen; LP = lamina propria. 
Supplementary Figure  4.













































































Supplementary Figure 4. Transcriptomic pathway analysis revealed 42 overrepresented 
pathways in the urinary bladder of diabetic compared to control rats.  (A) Ingenuity 
Pathway Analysis characterised the overrepresented canonical pathways, organised by 
pathway names (left y-axis) and p-value (top x-axis); the bars show the % of differentially 
expressed transcripts (bottom x-axis; Red: upregulated; Blue: downregulated) and total number 
of molecules ascribed in each canonical pathway are shown on right-y-axis. The changes in 
expression of deregulated transcripts in the altered (B) ‘Hepatic fibrosis/hepatic stellate cell 
activation’, (C) ‘Inhibition of matrix metalloproteases’ and (D) ‘Axonal guidance signalling’ 
pathways are arranged in order of significance (all p<0.05).  
Supplementary Figure  5.










































Supplementary Figure 5. Transcriptomic pathway analysis revealed 27 overrepresented 
pathways in the urinary bladder of sucrose-treated compared to control rats. Ingenuity 
Pathway Analysis characterised the overrepresented canonical pathways, organised by 
pathway names (left y-axis) and p-value (top x-axis); the bars show the % of differentially 
expressed transcripts (bottom x-axis; Red: upregulated; Blue: downregulated) and total number 
of molecules ascribed in each canonical pathway are shown on right-y-axis. 
Supplementary Figure  6.























































Supplementary Figure 6. Transcriptomic pathway analysis revealed 27 overrepresented 
pathways in the urinary bladder of sucrose-treated compared to diabetic rats.  Ingenuity 
Pathway Analysis characterised the overrepresented canonical pathways, organised by 
pathway names (left y-axis) and p-value (top x-axis); the bars show the % of differentially 
expressed transcripts (bottom x-axis; Red: upregulated; Blue: downregulated) and total number 
of molecules ascribed in each canonical pathway are shown on right-y-axis. The changes in 
expression of deregulated transcripts in the altered (B) ‘Hepatic fibrosis/hepatic stellate cell 
activation’, (C) ‘Inhibition of matrix metalloproteases’ pathways are arranged in order of 
significance (all p<0.05). 
Supplementary Figure  7
C D S
Supplementary Figure 7. Full cluster analysis demonstrates altered pattern of transcript 
expression in the bladder of control, diabetic and sucrose-treated rats. Unsupervised 
hierarchical clustering grouped transcripts into eight clusters. Rows are the mean transcript 
expression levels denoted as the z‐score displayed in colourised (High (Red) to Low (Blue)) 
scale. Columns are data from individual animals (Control n=6; Diabetic n=9; Sucrose-treated 




Supplementary Figure  8.
Supplementary Figure 8. STRING network analysis of Cluster 8. Interaction networks of 
the connected annotated molecules in Cluster 8. The most significant reactome pathway 
































































Supplementary Figure  9.
Supplementary Figure 9. qRT-PCR on genes from ‘Inhibition of matrix metalloproteinases’ 
pathway IPA pathway and Cluster 8.  Relative expression of (A) Timp1, (B) Timp2, (C) Timp3 (D) 
Mmp2, (E) Mmp14, (F) Mmp15, (G) Mmp16, (H) Mmp17, (I) Mmp19, (J) Mmp23, (K) Lrp1 and (L) 
Ctsk, normalised to Actb and expressed relative to control group expression.  Data are expressed as 
mean ± SD or median ± IQR and analysed by one way ANOVA followed by Tukey’s posthoc 






























Supplementary Figure 10.  Collagen I-immunoreactivity is downregulated in the detrusor 
muscle of diabetic rats.  Urinary bladder transverse sections were immunostained for collagen 
I.  Bladders from control (A, C) rats showed collagen I-immunoreactivity around muscle 
bundles in the detrusor muscle. Collagen I-immunoreactivity decreased in the detrusor muscle 
(E) of rats after 4 (B) and 16 weeks (D) of diabetes. Scale bar = 100 μm.  Data (E) are expressed 
as mean ± SD, analysed by t-test (*p<0.05, *** p<0.001). 
Detrusor muscle
Urothelium















Supplementary Figure  11.
Supplementary Figure 11. Cartoon schematic of bladder wall changes occurring in DM 
and polyuria alone. Detrusor muscle hypertrophy occurred similarly in models of STZ-
induced DM and rats with polyuria, with an increase in wall-thickness and bladder size. We 
found specific molecular changes occur in the urinary bladder in experimental DM. Gene array 
and bioinformatics highlighted dysregulation of ECM regulatory pathways and we found a loss 
of birefringent collagen fibrils (*) in the detrusor muscle of diabetic rats. AFM revealed a 
reduction in tissue stiffness in detrusor muscle of rats with DM, compared with control and 
sucrose-treated rats. Remodelling of the bladder wall, with the DM-associated changes in ECM 
homeostasis may contribute towards the reduced tissue rigidity. We suggest this may be central 
to causing the incomplete voiding reported in people who have had long-term bladder damage 
associated with diabetes mellitus.  
 
 
